FDA授予OPN-6602孤儿药资格用于治疗多发性骨髓瘤
OPN-6602 (Opna Bio) 获得 FDA 孤儿药资格 (ODD)，用于治疗复发/难治性多发性骨髓瘤 (RRMM) 患者。该资格基于 1 期临床试验 (NCT06433947) 的结果。
eLife2 天
Synaptic deregulation of cholinergic projection neurons causes olfactory dysfunction across ...
A new Drosophila collection of Parkinsonism models reveals early synaptic cholinergic projection neuron dysfunction, linking synaptic failure to later dopaminergic decline, highlighting a role for ...
Innovative model shows how optic tract injuries can heal through axonal rewiring
A research team has established an innovative intracranial pre-olivary pretectal nucleus (OPN) optic tract injury model ...